B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
Innate Pharma Q1 Earnings Call Highlights
Innate Pharma Reports First Quarter 2026 Business Update and Financial Results
Number of Shares and Voting Rights of Innate Pharma as of April 16, 2026
Innate Pharma Announces Conference Call and Webcast for Q1 2026 Business Update
Innate Pharma to Participate in the D. Boral Capital Global Conference
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026
Number of Shares and Voting Rights of Innate Pharma as of April 9, 2026
Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event
Innate Pharma to Participate in the Kempen Life Sciences Conference
Innate Pharma Files Its 2025 Universal Registration Document (Document D'enregistrement Universel) and 2025 Form 20-f Annual Report
Innate Pharma Q4 Earnings Call Highlights
Innate Pharma S.A. (IPHA) Q4 2025 Earnings Call Transcript
Innate Pharma Reports Full Year 2025 Financial Results and Business Update
Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results
Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026
Innate Pharma to Participate in the Leerink Partners Global Healthcare Conference
Number of Shares and Voting Rights of Innate Pharma as of December 31, 2025
Number of Shares and Voting Rights of Innate Pharma as of December 18, 2025
Innate Pharma Releases Its 2026 Financial Calendar
Number of Shares and Voting Rights of Innate Pharma as of November 27, 2025
Innate Pharma S.A. (IPHA) Q3 2025 Earnings Call Transcript
Innate Pharma Reports Third Quarter 2025 Business Update and Financial Results
Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL
Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business Updates
Innate Pharma S.A. (IPHA) Analyst/Investor Day Transcript
Innate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025
Innate Pharma S.A. (IPHA) Q2 2025 Earnings Call Transcript
Innate Pharma Reports First Half 2025 Business Update and Financial Results
Innate Pharma Announces Its Participation in the 25th Edition of the European Midcap Event
Innate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business Update
Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference
Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
Outcome of Innate Pharma's 2025 Annual General Meeting
Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
Innate Pharma S.A. (IPHA) Q1 2025 Earnings Call Transcript
Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
Innate Pharma announces conference call and webcast for Q1 2025 business update
Innate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F
Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
Innate Pharma Announces €15M Investment by Sanofi
Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi's Intention to Make a Strategic Investment in the Company
Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025